Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy

Research output: Contribution to journalArticle

Armando Cevenini, Christian Celia, Stefania Orrù, Daniela Sarnataro, Maddalena Raia, Valentina Mollo, Marcello Locatelli, Esther Imperlini, Nicoletta Peluso, Rosa Peltrini, Enrica De Rosa, Alessandro Parodi, Luigi Del Vecchio, Luisa Di Marzio, Massimo Fresta, Paolo Antonio Netti, Haifa Shen, Xuewu Liu, Ennio Tasciotti, Francesco Salvatore

Mesoporous silicon microparticles (MSMPs) can incorporate drug‐carrying nanoparticles (NPs) into their pores. An NP‐loaded MSMP is a multistage vector (MSV) that forms a Matryoshka‐like structure that protects the therapeutic cargo from degradation and prevents its dilution in the circulation during delivery to tumor cells. We developed an MSV constituted by 1 μm discoidal MSMPs embedded with PEGylated liposomes containing oxaliplatin (oxa) which is a therapeutic agent for colorectal cancer (CRC). To obtain extra‐small liposomes able to fit the 60 nm pores of MSMP, we tested several liposomal formulations, and identified two optimal compositions, with a prevalence of the rigid lipid 1,2‐distearoyl‐sn‐glycero‐3‐phosphocholine and of 1,2‐distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐N‐[methoxy(polyethylene glycol)‐2000]. To improve the MSV assembly, we optimized the liposome‐loading inside the MSMP and achieved a five‐fold increase of the payload using an innovative lyophilization approach. This procedure also increased the load and limited dimensional changes of the liposomes released from the MSV in vitro. Lastly, we found that the cytotoxic efficacy of oxa‐loaded liposomes and‐oxa‐liposome‐MSV in CRC cell culture was similar to that of free oxa. This study increases knowledge about extra‐ small liposomes and their loading into porous materials and provides useful hints about alternative strategies for designing drug‐encapsulating NPs.

Original languageEnglish (US)
Article number559
Pages (from-to)1-28
Number of pages28
JournalPharmaceutics
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2020

Altmetrics

Cite this

Standard

Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy. / Cevenini, Armando; Celia, Christian; Orrù, Stefania; Sarnataro, Daniela; Raia, Maddalena; Mollo, Valentina; Locatelli, Marcello; Imperlini, Esther; Peluso, Nicoletta; Peltrini, Rosa; De Rosa, Enrica; Parodi, Alessandro; Del Vecchio, Luigi; Di Marzio, Luisa; Fresta, Massimo; Netti, Paolo Antonio; Shen, Haifa; Liu, Xuewu; Tasciotti, Ennio; Salvatore, Francesco.

In: Pharmaceutics, Vol. 12, No. 6, 559, 01.06.2020, p. 1-28.

Research output: Contribution to journalArticle

Harvard

Cevenini, A, Celia, C, Orrù, S, Sarnataro, D, Raia, M, Mollo, V, Locatelli, M, Imperlini, E, Peluso, N, Peltrini, R, De Rosa, E, Parodi, A, Del Vecchio, L, Di Marzio, L, Fresta, M, Netti, PA, Shen, H, Liu, X, Tasciotti, E & Salvatore, F 2020, 'Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy' Pharmaceutics, vol. 12, no. 6, 559, pp. 1-28. https://doi.org/10.3390/pharmaceutics12060559

APA

Cevenini, A., Celia, C., Orrù, S., Sarnataro, D., Raia, M., Mollo, V., ... Salvatore, F. (2020). Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy. Pharmaceutics, 12(6), 1-28. [559]. https://doi.org/10.3390/pharmaceutics12060559

Vancouver

Cevenini A, Celia C, Orrù S, Sarnataro D, Raia M, Mollo V et al. Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy. Pharmaceutics. 2020 Jun 1;12(6):1-28. 559. https://doi.org/10.3390/pharmaceutics12060559

Author

Cevenini, Armando ; Celia, Christian ; Orrù, Stefania ; Sarnataro, Daniela ; Raia, Maddalena ; Mollo, Valentina ; Locatelli, Marcello ; Imperlini, Esther ; Peluso, Nicoletta ; Peltrini, Rosa ; De Rosa, Enrica ; Parodi, Alessandro ; Del Vecchio, Luigi ; Di Marzio, Luisa ; Fresta, Massimo ; Netti, Paolo Antonio ; Shen, Haifa ; Liu, Xuewu ; Tasciotti, Ennio ; Salvatore, Francesco. / Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy. In: Pharmaceutics. 2020 ; Vol. 12, No. 6. pp. 1-28.

BibTeX

@article{e7b55a7d492b4203913b4fbce6f9b5be,
title = "Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy",
abstract = "Mesoporous silicon microparticles (MSMPs) can incorporate drug‐carrying nanoparticles (NPs) into their pores. An NP‐loaded MSMP is a multistage vector (MSV) that forms a Matryoshka‐like structure that protects the therapeutic cargo from degradation and prevents its dilution in the circulation during delivery to tumor cells. We developed an MSV constituted by 1 μm discoidal MSMPs embedded with PEGylated liposomes containing oxaliplatin (oxa) which is a therapeutic agent for colorectal cancer (CRC). To obtain extra‐small liposomes able to fit the 60 nm pores of MSMP, we tested several liposomal formulations, and identified two optimal compositions, with a prevalence of the rigid lipid 1,2‐distearoyl‐sn‐glycero‐3‐phosphocholine and of 1,2‐distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐N‐[methoxy(polyethylene glycol)‐2000]. To improve the MSV assembly, we optimized the liposome‐loading inside the MSMP and achieved a five‐fold increase of the payload using an innovative lyophilization approach. This procedure also increased the load and limited dimensional changes of the liposomes released from the MSV in vitro. Lastly, we found that the cytotoxic efficacy of oxa‐loaded liposomes and‐oxa‐liposome‐MSV in CRC cell culture was similar to that of free oxa. This study increases knowledge about extra‐ small liposomes and their loading into porous materials and provides useful hints about alternative strategies for designing drug‐encapsulating NPs.",
keywords = "Colon cancer, Liposome, Mesoporous silicon microparticle, Multistage vector, Nanoparticle, Oxaliplatin",
author = "Armando Cevenini and Christian Celia and Stefania Orr{\`u} and Daniela Sarnataro and Maddalena Raia and Valentina Mollo and Marcello Locatelli and Esther Imperlini and Nicoletta Peluso and Rosa Peltrini and {De Rosa}, Enrica and Alessandro Parodi and {Del Vecchio}, Luigi and {Di Marzio}, Luisa and Massimo Fresta and Netti, {Paolo Antonio} and Haifa Shen and Xuewu Liu and Ennio Tasciotti and Francesco Salvatore",
year = "2020",
month = "6",
day = "1",
doi = "10.3390/pharmaceutics12060559",
language = "English (US)",
volume = "12",
pages = "1--28",
journal = "Pharmaceutics",
issn = "1999-4923",
number = "6",

}

RIS

TY - JOUR

T1 - Liposome‐embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy

AU - Cevenini, Armando

AU - Celia, Christian

AU - Orrù, Stefania

AU - Sarnataro, Daniela

AU - Raia, Maddalena

AU - Mollo, Valentina

AU - Locatelli, Marcello

AU - Imperlini, Esther

AU - Peluso, Nicoletta

AU - Peltrini, Rosa

AU - De Rosa, Enrica

AU - Parodi, Alessandro

AU - Del Vecchio, Luigi

AU - Di Marzio, Luisa

AU - Fresta, Massimo

AU - Netti, Paolo Antonio

AU - Shen, Haifa

AU - Liu, Xuewu

AU - Tasciotti, Ennio

AU - Salvatore, Francesco

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Mesoporous silicon microparticles (MSMPs) can incorporate drug‐carrying nanoparticles (NPs) into their pores. An NP‐loaded MSMP is a multistage vector (MSV) that forms a Matryoshka‐like structure that protects the therapeutic cargo from degradation and prevents its dilution in the circulation during delivery to tumor cells. We developed an MSV constituted by 1 μm discoidal MSMPs embedded with PEGylated liposomes containing oxaliplatin (oxa) which is a therapeutic agent for colorectal cancer (CRC). To obtain extra‐small liposomes able to fit the 60 nm pores of MSMP, we tested several liposomal formulations, and identified two optimal compositions, with a prevalence of the rigid lipid 1,2‐distearoyl‐sn‐glycero‐3‐phosphocholine and of 1,2‐distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐N‐[methoxy(polyethylene glycol)‐2000]. To improve the MSV assembly, we optimized the liposome‐loading inside the MSMP and achieved a five‐fold increase of the payload using an innovative lyophilization approach. This procedure also increased the load and limited dimensional changes of the liposomes released from the MSV in vitro. Lastly, we found that the cytotoxic efficacy of oxa‐loaded liposomes and‐oxa‐liposome‐MSV in CRC cell culture was similar to that of free oxa. This study increases knowledge about extra‐ small liposomes and their loading into porous materials and provides useful hints about alternative strategies for designing drug‐encapsulating NPs.

AB - Mesoporous silicon microparticles (MSMPs) can incorporate drug‐carrying nanoparticles (NPs) into their pores. An NP‐loaded MSMP is a multistage vector (MSV) that forms a Matryoshka‐like structure that protects the therapeutic cargo from degradation and prevents its dilution in the circulation during delivery to tumor cells. We developed an MSV constituted by 1 μm discoidal MSMPs embedded with PEGylated liposomes containing oxaliplatin (oxa) which is a therapeutic agent for colorectal cancer (CRC). To obtain extra‐small liposomes able to fit the 60 nm pores of MSMP, we tested several liposomal formulations, and identified two optimal compositions, with a prevalence of the rigid lipid 1,2‐distearoyl‐sn‐glycero‐3‐phosphocholine and of 1,2‐distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐N‐[methoxy(polyethylene glycol)‐2000]. To improve the MSV assembly, we optimized the liposome‐loading inside the MSMP and achieved a five‐fold increase of the payload using an innovative lyophilization approach. This procedure also increased the load and limited dimensional changes of the liposomes released from the MSV in vitro. Lastly, we found that the cytotoxic efficacy of oxa‐loaded liposomes and‐oxa‐liposome‐MSV in CRC cell culture was similar to that of free oxa. This study increases knowledge about extra‐ small liposomes and their loading into porous materials and provides useful hints about alternative strategies for designing drug‐encapsulating NPs.

KW - Colon cancer

KW - Liposome

KW - Mesoporous silicon microparticle

KW - Multistage vector

KW - Nanoparticle

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=85086670952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086670952&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics12060559

DO - 10.3390/pharmaceutics12060559

M3 - Article

VL - 12

SP - 1

EP - 28

JO - Pharmaceutics

T2 - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 6

M1 - 559

ER -

ID: 64294261